T3D2862

2904 T3D2862

Tizanidine

Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. 51322-75-9

5487

C9H8ClN5S

253.018890 White powder.

1.33e-01 g/L

Oral

Tizanidine reduces spasticity by increasing presynaptic inhibition of motor neurons through agonist action at a2-adrenergic receptor sites.

Route of Elimination: Approximately 95% of an administered dose is metabolized. Half Life: 2.5 hours No indication of carcinogenicity to humans (not listed by IARC).

For the management of increased muscle tone associated with spasticity

May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.

Should overdose occur, basic steps to ensure the adequacy of an airway and the monitoring of cardiovascular and respiratory systems should be undertaken. In general, symptoms resolve within one to three days following discontinuation of tizanidine and administration of appropriate therapy. Due to the similar mechanism of action, symptoms and management of tizanidine overdose are similar to those following clonidine overdose. (L1712)

2009-07-21T20:27:26Z

2014-12-24T20:25:52Z

Tizanidine

C07452

63629

Tizanidine

DB00697

true

ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1

C9H8ClN5S

InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)

InChIKey=XFYDIVBRZNQMJC-UHFFFAOYSA-N

253.711

253.018893678

Exogenous Solid 1.4

HMDB14835

CHEMBL1079

5287

Pavel Hradil, Lubomir Kvapil, Martin Grepl, Jan Novotny, “METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE.” U.S. Patent US20110263863, issued October 27, 2011.